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Placement of lumen‑apposing metal stents to drain
pseudocysts and walled‑off pancreatic necrosis can be
safely performed on an outpatient basis: A multicenter
study
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ABSTRACT
Backgrounds and Objectives: No study on the use of lumen‑apposing fully covered self‑expanding metal stent (LAMS)
to drain pancreatic fluid collections (PFCs) has evaluated outcomes of patients in the outpatient setting. The objective of
this multicenter study was to evaluate the clinical outcomes, success rate, and adverse events of the LAMS for endoscopic
ultrasound (EUS)‑guided transmural drainage of patients with symptomatic PFCs on an inpatient versus an outpatient basis.
Methods: This was a multicenter, retrospective study conducted at 4 tertiary care centers. Results: We identified eighty
patients with PFCs in whom EUS‑guided transmural drainage using the LAMS was performed. The mean age of the patients
was 53.1 years old. Mean size of the PFC was 11.8 ± 5.1 cm. A total of 33 patients had PFCs drained in an outpatient setting
while 47 patients underwent PFC drainage as inpatients. The overall technical success (ability to access and drain a PFC by
placement of transmural stents) was 98.7% (79 patients). There was no statistically significant difference in the technical
success rate between the inpatient and outpatient groups (100% vs. 98%, respectively, P = 1). There was no significant
difference in resolution of PFCs in the inpatient and outpatient groups (91% vs. 87% respectively; P = 1). The number
of procedures required for PFC resolution was significantly lower in the inpatient group as compared to the outpatients
(2.3 vs. 3.1 respectively, P = 0.025). Procedure‑related adverse events were significantly lower in the inpatient group compared
to the outpatient group (P < 0.01). There was no significant difference in the 2 groups in terms of development of adverse
events requiring endoscopic reintervention within 30 days of initial stent placement (P = 0.69). Conclusion: This study shows
that LAMS placement for PFCs can be performed safely on an outpatient basis with overall technical and clinical outcomes
that are comparable to those seen in inpatients.
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INTRODUCTION
Pancreatic fluid collections (PFCs) are commonly
encountered clinical entities and are thought to arise
due to pancreatic duct damage in patients with acute
or chronic pancreatitis, pancreatic trauma, iatrogenic
injuries (i.e., surgery), and in patients with a disrupted
pancreatic duct.[1,2] PFCs are generally divided into two
groups: pancreatic pseudocysts (PPs) and walled‑off
necrosis (WON). PPs are defined as of fluid collections
in the peripancreatic tissues that are surrounded by a
well‑defined wall and contain no solid material. WONs
are defined as consisting of necrotic tissue contained
within a wall of reactive tissue.[1] Most PFCs are small
and asymptomatic and many resolve spontaneously.
Nonetheless, some PFCs become symptomatic usually
due to a large size that produces when they increase in
size or become infected, leading to symptoms including
abdominal pain, early satiety, gastric outlet obstruction,
biliary obstruction with concomitant jaundice, and
sepsis.[3]
The current management options for symptomatic
PFCs include endoscopic, surgical, and percutaneous
drainage.[4‑6] The surgical approach is most invasive and
carries a high mortality and morbidity. PFCs drained
through the percutaneous approach are at risk of fistula
formation, cyst recurrence, and infections.[7]
In the last decade, endosonography‑guided drainage of
PFCs through the placement of transmural stents has
become the procedure of choice in many tertiary care
centers, often viewed as the first‑line therapy instead of
surgical or interventional radiology approaches. Recently,
a novel “saddle‑shaped” lumen‑apposing fully covered
self‑expanding metal stent (LAMS) with both proximal
and distal anchor flanges has been demonstrated to
be both safe and effective for endoscopic transmural
drainage of PPs and WONs and is often used in
place of a covered biliary metal stent or double‑pigtail
stents.[8‑11]
To date, no study on the use of LAMS to drain PFCs
has evaluated the role and outcomes of patients in the
outpatient setting. It is unknown if LAMS placement
warrants inpatient admission at the time of placement
or is safe to be performed in outpatients. Other
high‑risk endoscopic procedures, including ERCP,
percutaneous endoscopic gastrostomy, and interventional
endoscopic ultrasound (EUS) procedures, are routinely
performed in the outpatient setting. The objective of

this large multicenter study was to evaluate the overall
clinical outcomes, success rate, and adverse events of
the LAMS for EUS‑guided transmural drainage of
patients with symptomatic PFCs in the United States, in
those undergoing the procedure on an inpatient versus
an outpatient basis.
METHODS
This was a multicenter, retrospective study conducted
at 4 tertiary care centers. The study was approved by
the Institutional Review Boards in all centers. The
study concept, hypothesis, and design were investigator
initiated and no ﬁnancial support was received.
The endoscopy database at Thomas Jefferson University
Hospital, University of Utah Hospitals and Clinics,
Borland‑Groover Clinic and California Pacific Medical
Center was queried for all patients who had undergone
EUS‑guided drainage of PFCs (i.e., PP and WON)
using the LAMS between February 2012 and June
2016. Only patients with a 3‑month or greater
follow‑up were included in the study. WON consisted
of a mature, encapsulated collection of pancreatic,
and/or peripancreatic necrotic tissue contained within
an enhancing wall of reactive tissue. PP was defined as
an encapsulated collection of fluid with a well‑defined
inflammatory wall usually outside the pancreas with
minimal or no necrosis (as per the Revised Atlanta
Classification).[1]
Inpatients were already admitted at the time of the
procedure. Outpatients were patients who came in as
outpatients to the endoscopy suite and in whom there
were no plans to admit unless a complication occurred.
Patients were hospitalized preprocedure if they had
intractable pain, evidence of fevers, or inability to take
oral intake or other symptoms of concern. Patients
were admitted if they developed a complication from
their endoscopy. PFCs were characterized by a variety
of techniques including magnetic resonance imaging
or computed tomography (CT) as well as EUS on
the day of their initial drainage procedure. Indications
for drainage of PFCs were as follows: (1) signs or
symptoms of infection in the PFC, (2) abdominal pain
felt to be attributable to the PFC, (3) gastric outlet
or biliary obstruction due to extrinsic compression
through the PFC, (4) ongoing systemic illness,
anorexia, nausea, vomiting, and weight loss, or
(5) rapidly enlarging PFCs.[12] Patients with interposed
vessels or significant varices, cystic neoplasms,
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coagulopathy (international normalized ratio >1.6), and
significant thrombocytopenia (platelets <50,000/mm3),
or cyst imaging showing that the PFC wall was not in
proximity (>1 cm) to the gastric or duodenal lumen
were excluded from the study. Data were obtained
from inpatient and outpatient hospital records to
collect procedural details and overall clinical course
of the patient. In addition, records from hospitals in
our region are available through our electronic medical
record to facilitate data capture from events occurring
beyond the site of endoscopic intervention.

Description of the lumen‑apposing fully covered
self‑expanding metal stent

The LAMS (AXIOS; Boston Scientific, Natick MA)
utilized in this study is a saddle‑shaped, braided flexible
stent made of nitinol that is fully covered with a silicon
membrane. The stent is manufactured with bilateral
double‑walled anchoring flanges designed to hold the
stomach or duodenal wall in close apposition to PFC
wall.[13] The stent is 10 mm in length and is available in
10 or 15 mm diameter sizes.

Techniques

All patients underwent procedures by endoscopists
with >5 years of active EUS practice (D.G.A., A.A.S.,
J.N., J.N.S., K.F.B., Y.M.B.). All endoscopists have prior
experience with PFC drainage through traditional
techniques. PFC drainage was performed in all cases
through a therapeutic linear array echoendoscope (GFUCT180; Olympus, USA). All procedures were
performed under general anesthesia and all patients
were administered broad‑spectrum antibiotics during
and after the procedure to decrease the risk of
infection. A careful EUS examination before LAMS
placement was used to determine the optimal puncture
site of the cyst in all patients. Color Doppler was
used to exclude interposed vessels at the puncture site
19‑gauge EUS fine‑needle aspiration needles were used
to perform the initial puncture into the cyst under
real‑time imaging. The cyst contents were then aspirated
for visual inspection (e.g., viscosity, debris, pus) and sent
for fluid analysis (e.g., tumor markers, cytology, culture)
if felt to be warranted the discretion of the
endoscopist. A 0.035” guidewire was then inserted
through the needle and allowed to coil several times
into the cyst cavity under EUS and fluoroscopic
guidance. The needle was then withdrawn over the
wire. Cystgastrostomy tract dilation was performed with
either an 8F–10F Soehendra dilator (Cook Medical,
Winston‑Salem NC, USA) or a 6 mm or 8 mm
38

wire‑guided balloon (Hurricane, Boston Scientific,
Natick MA, USA) based on the preference of the
endoscopist. After the cystgastrostomy was dilated, the
LAMS delivery catheter was advanced over the wire and
into the cyst cavity. Of note, the LAMS device used in
this study was the so‑called “Cold‑Axios” that did not
have a diathermic tip on the catheter. Once the LAMS
catheter was in good position in the PFC, the distal
half of the stent was deployed under EUS guidance
with or without fluoroscopic guidance at the discretion
of the endoscopist. Deployment of the proximal flange
of the stent was then performed under endoscopic
guidance. The selection of stent diameter was at the
discretion of the endoscopist; although, in general,
if the PFC was felt to contain significant debris, a
15 mm LAMS was placed to facilitate the future
necrosectomy procedures. The deployed stent lumen
was then dilated up to 10 or 15 mm with a controlled
radial expansion balloon (Boston Scientific) to allow for
optimal stent luminal expansion if felt to be indicated
by the endoscopist.
In patients with WON, subsequent endoscopic
necrosectomy procedures were performed using a
standard upper endoscope advanced through the
LAMS at times dictated by the preference of the
endoscopist, usually every 3–7 days until complete
resolution of the necrotic cavity as confir med
endoscopically and/or by results obtained through
cross‑sectional imaging.
Any complication occurring or after during the
procedure including perforation, bleeding, infection,
development of pancreatitis or worsening of existing
pancreatitis, hypotension, or respiratory distress was
carefully documented. The electronic medical records of
hospital admissions, emergency room visits, and/or clinic
visits were also compiled in an effort to identify any
delayed complication (up to 30 days after procedure).

Patients’ follow‑up

All patients underwent contrast‑enhanced CT of
the abdomen at 4–8 weeks after LAMS placement
followed in an outpatient clinic visit. LAMS removal
was performed when complete cyst decompression
was achieved, i.e., the PFC had completed resolved
without any residual intracystic solid or fluid component
remaining.

Outcomes measures

Technical success was defined as the ability to place and
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deploy a LAMS stent transmurally without difficulty.
Successful drainage of the PFC based on endoscopy
or cross‑sectional imaging results 1 month after the
therapy with at least a 50% reduction in PFC size and
resolution of clinical symptoms as documented in clinic
follow‑up notes, respectively.[14]
Immediate procedure‑related adverse events were
defined as those that occurred within 1 week after the
procedure. Reinterventions included the need to replace
or remove migrated LAMS, repeat PFC drainage due
to LAMS stent occlusion, cyst cavity infection with
inadequate drainage through the LAMS, enlarging cyst
size despite LAMS placement, or worsening of clinical
symptoms due to the PFC.
The primary outcome of this study was to evaluate
the overall long‑ter m success and adverse event
rate of LAMS usage in inpatients versus outpatients.
Patients were considered inpatients if they were either
inpatients at the time of PFC placement or admitted
to the hospital after LAMS placement. Patients were
considered outpatients if they came from home for
their LAMS placement and returned home the same
day without being admitted to the hospital at all.
Outpatients were carefully monitored for any adverse
event that would require inpatient admission after being
discharged to home.
Long‑ter m success was defined as complete
resolution of the pseudocyst and resolution of the
patient’s symptoms without need for reintervention
at 3 months following initial treatment as
demonstrated by ambulatory clinic follow‑up and
cross‑sectional imaging. Secondary outcomes evaluate
included adverse events, number of endoscopic
reinterventions, and PFC recurrence rates after the
stent removal.

Statistical analysis

This was a retrospective cohort study. We divided the
subjects into 2 groups according to the setting of the
PFC drainage 1) outpatient and 2) inpatient. Outcomes
between the groups were compared using the Student’s
t test for continuous variables and the Chi-square test
for categorical variables. Generalized linear modeling
(GLM) were performed on categorical and continuous
variables, respectively, in order to assess any difference
in outcomes in the outpatient versus inpatient setting.
Statistical significance was determined a priori at P ≤
0.05.

RESULTS

Patient demographics and pancreatic fluid collection
characteristics

From February 2012 to June 2016, we identified
80 patients with PFCs in whom EUS‑guided
transmural drainage using the LAMS was performed.
All PFCs developed after the episodes of acute
pancreatitis. The mean age of the patients was
53.1 ± 15 years and 40% were female. The etiology
of pancreatitis was gallstone (49%), alcohol (30%),
idiopathic (8%), drug‑induced (2%), autoimmune (1%),
and hypertriglyceridemia (10%). The clinical
presentation in patients that required drainage included
abdominal pain, nausea and vomiting, anorexia and
early satiety, and biliary obstruction [Table 1].
PFCs were located in the pancreatic head (5%),
pancreatic body and tail (84%), and involved the
pancreatic head/body/tail (11%). Mean size of the
PFC was 11.8 ± 5.1 cm in the long axis (range,
4.8–25 cm).
Of the eighty patients, 12 presented with PP and
68 patients had WONs. There was no significant
difference in sex, etiology, or cyst size between
patients with PP and WON. Patients with WON were
younger (51.7 vs. 61 years respectively, P = 0.04) and
were predominantly white (82.3% vs. 50% respectively,
P = 0.02) when compared to those with PP. Twenty
percent of patients had failed prior endoscopic or
inter ventional radiology inter vention before our
endoscopist intervention.

Inpatients and outpatients that underwent pancreatic
fluid collection drainage

There were 33 patients whose PFC cavity was
drained in an outpatient setting while 47 patients
underwent PFC drainage using the LAMS as
inpatients. Transgastric drainage was perfor med
in 74 patients (92.5%), 5 patients (6.25%) had
transduodenal drainage, and 1 (1.25%) patients had
multiport stent drainage/debridement. Seventy‑two
patients had a 15 mm wide x10 mm long LAMS placed
and 8 had a 10 mm × 10 mm diameter LAMS placed.
The median duration that the stents remained implanted
was 1 month (range, 1–6 months). Nine patients had a
concomitant ERP with transpapillary pancreatic stent
placement for a concomitant pancreatic duct leak
contributing to WONs as seen on MRCP. Twenty‑two
patients had placement of an 8Fr nasocystic catheter
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due to the presence of large amount of solid debris
inside the WON cavity and nasocystic lavage was
performed with bolus perfusions of saline for 1–2 days
after initial LAMS placement [Table 2].
The overall technical success (ability to access and drain
a PFC by the placement of transmural stents) was
98.7% (79 patients). There was no statistically significant
difference in the technical success rate between
the inpatient and outpatient groups (100% vs. 98%
respectively, P = 1). Unsuccessful placement of the
LAMS in 1 patient in the outpatient group was as a
result of stent maldeployement.

Long‑term follow‑up (6 months)

On 6‑month follow‑up, overall clinical success with
successful eradication of the PFC was achieved
in 72/80 (90%) patients. There was no difference
in the percentage of inpatients (84.8%) and
outpatients (85.1%) who were found to have WON.
Similarly, there was no difference in the number of
patients with WON in whom elective direct endoscopic
necrosectomy (DEN) was performed when comparing
the inpatient and outpatient groups (78.8% vs. 78.7%,
respectively; P = 1). There was no significant difference
in complete resolution of PFCs in the inpatient and
outpatient groups (91% vs. 87%, respectively; P = 1).
The mean number of procedures required for PFC
resolution after initial stent placement was significantly
lower in the inpatient group as compared to the
outpatients (2.3 vs. 3.1, respectively, P = 0.025).
There was no significant difference in resolution of
WON between patients with or without nasocystic
tube irrigation placed at the time of initial procedure
(93.2% vs. 87.4%, respectively; P = 0.26). Similarly,
there was no significant difference in resolution of the
WON between patient with or without transpapillary
pancreatic stent placement at the time of initial
procedure (90% vs. 88.7%; P = 1). No recurrence of
WON or a pseudocyst was seen after the removal of
the stents in any of the groups. These findings are
summarized in Table 3.

Procedure‑related adverse events

There was one procedure‑related adverse event in
the inpatient group; this was significant hemorrhage
due to inadvertent puncture of an artery, which
was successfully treated with coil embolization by
interventional radiology [Table 2].
40

There were eight procedure‑related adverse events in
the outpatient group: 3 perforations, 6 episodes of
clinically significant bleeding at the cystenterostomy/
stent site, 1 suprainfection, and 3 episodes of self‑limited
bleeding at the stent site after the procedure that resolved
with local injection of epinephrine. One 63 year old
male patient who developed a perforation after stent
maldeployement had the perforation closed using an
over‑the‑scope clip; he then had placement of a fully
covered biliary metal stent through a new puncture
site to drain the WON; this patient did well and had
complete resolution of his WON. Two patients developed
pneumoperitoneum after failed transmural drainage/
debridement due to LAMS maldeployement. The LAMS
were removed. The operators then could not successfully
advance the guidewire into the WON cavity. The
guidewire was repeatedly advanced into the abdominal
cavity despite multiple attempts; therefore, another stent
could not be placed safely to drain the pseudocyst. These
patients were sent to surgery and had primary repair of
the gastric perforation and underwent cystgastrostomy.
Procedure‑related adverse events were significantly
lower in the inpatient group compared to the outpatient
group (P < 0.01). There was no procedure‑related
mortality in either group.

Late adverse events after initial stent placement

In the inpatient group, 3/33 (9%) patients required
reintervention due to the following reasons: 1 patient
had occlusion of the LAMS as a result of necrotic
debris and 2 patients had infection of the PFC cavity
requiring endoscopic debridement and irrigation.
The need for endoscopic reintervention in the outpatient
group was seen in 3/47 (6%) of cases due to the
following reasons: one patient had occlusion of the LAMS
as a result of necrotic debris and 2 patients had infection
of the PFC cavity requiring endoscopic debridement
and irrigation. There was no significant difference in the
2 groups in terms of development of adverse events
requiring endoscopic reintervention within 30 days of
initial stent placement (P = 0.69). Patients who had
secondary infection of the PFC as a result of occluded
stents were all successfully managed by endoscopic
replacement of stents and placement of a nasocystic drain.
DISCUSSION
The use of LAMS to endoscopically drain and
debride PFCs including PP and WON is undergoing
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a period of exponential growth with this technology
rapidly disseminating into widespread clinical practice.
Historically, PFC drainage and LAMS placement have
often perceived as a procedure that frequently warrants
inpatient hospitalization. This study demonstrates that
the placement of LAMS in patients with PFCs can be
safely performed on an outpatient basis and does not
automatically warrant inpatient hospitalization.
This study included 80 patients, the vast majority of
whom had WON. As such, this represents a cohort
of, overall, significantly ill patients. The overall
technical success in our study was very high (98.7%)
and was similar to, or better than, that seen in other
studies of the use of LAMS to drain PFCs. [15‑17]
There was no statistically significant difference in
the technical success rate between the inpatient and
outpatient groups. The proportion of patients with
WON was the same in our inpatient and outpatient
subgroups as was the percentage of patients in both
groups who required DEN, further demonstrating that
outpatient LAMS placement and debridement can be
performed in patients with sequelae of severe acute
pancreatitis.
Our study showed no significant difference in the
rate of complete resolution of PFCs in the inpatient
and outpatient groups (91% vs. 87%). The number of
procedures required for PFC resolution after the initial
stent placement was statistically significantly lower in the
inpatient group as compared to the outpatient although
this essentially amounted to only one more procedure in
the outpatient group (approximately 2 vs. 3, respectively).
The reason for this difference in total number of
procedure required is unclear at this time.
There were more adverse events related to the LAMS
placement itself in the outpatient group, but there was
no significant difference in the 2 groups in terms of
development of adverse events requiring endoscopic
reintervention within 30 days of initial stent placement.
It is unclear why there were more adverse events during
the LAMS placement in the outpatient group although
patients who are referred for planned outpatient
LAMS procedures can always be admitted afterward
for subsequent observation and/or care as needed.
The fact that the rate of delayed adverse events was
the same between the two groups argues that in
patients who undergo an uneventful LAMS procedure
further demonstrates that these patients can be safely
discharged without inordinate fear of poor outcomes.

Table 1. Patient demographics and pancreatic fluid
collection characteristics
Patients (n=80)
Gender (%)
Female
Male
Mean age (years)
Race (%)
White
Black
Hispanic
Other
Pancreatitis etiology (%)
Gallstone
Alcohol
Idiopathic
Trauma
Autoimmune
High triglycerides
Drug related
Mean WON long axis measurement (mm)
Site of WON (%)
Pancreatic head
Pancreatic body/tail
Pancreatic head/body/tail

40
60
53.1
78
6
10
6
49
30
8
0
1
10
2
118
5
84
11

WON: Walled‑off necrosis

Table 2. Procedural characteristics and adverse
events
Out patients
(n=33)

In patients
(n=47)

94
6
98

91
9
100

10
2
4

3
0
0

Site of cyst‑enterostomy (%)
Stomach
Duodenal bulb
Procedural technical success (%)
Procedural adverse events
Bleeding
Suprainfection
Perforation

Table 3. Results of endoscopic ultrasound‑guided
drainage/debridement of pancreatic fluid collections
Outpatients
(n=33)

Inpatients
(n=47)

3.1

2.3

87

91

8.5

6

0

0

Mean number of endoscopic
sessions for PFC resolution
Success rate for endoscopic
drainage of WON (%)
Patients that required
radiological and/or surgery
for final PFC therapy (%)
Recurrence of PFC
after endoscopic stent
removal (%)

PFC: Pancreatic fluid collection, WON: Walled‑off necrosis

Our study shows that as experience grows with
interventional EUS procedures in general, and PFC
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drainage specifically, our comfort level with performing
these procedures in outpatients can grow as well.
A similar evolution occurred in the world of ERCP
approximately 2 decades ago. Previously, ERCP‑based
maneuvers such as sphincterotomy, stone extraction,
and stent placement were felt to warrant subsequent
inpatient admission and observation. Studies from the
1990s showed that these and other maneuvers could
be safely performed on outpatients. [12-14,18] Similar
findings were seen when laparoscopic cholecystectomy
transitioned from a purely inpatient procedure to a
predominately outpatient procedure.[19‑21]
Overall, this study shows that LAMS placement for
PFCs including both PP and WON can be performed
safely on an outpatient basis with overall technical
and clinical outcomes that are comparable to those
seen in inpatients. Patients with a planned outpatient
LAMS procedure who develop an adverse event during
the procedure can always be admitted for inpatient
care afterward. Stable outpatients who tolerate LAMS
placement without difficulty can be safely discharged
home on the same day as their procedure.

2.
3.
4.

5.

6.

7.

8.

9.

10.

CONCLUSION

11.

This study shows that LAMS placement for PFCs can
be performed safely on an outpatient basis with overall
technical and clinical outcomes that are comparable to
those seen in inpatients.
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